echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > New monoclonal antibody treatment of yellow fever: safe and effective.

    New monoclonal antibody treatment of yellow fever: safe and effective.

    • Last Update: 2020-08-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Yellow fever (YF) is a viral disease found in tropical regions of Africa and the Americas.
    the disease mainly affects humans and monkeys and is transmitted through the bite of the Aedes aegypti mosquito.
    the disease can lead to highly destructive outbreaks that can be prevented and controlled through mass vaccination campaigns. The initial symptoms of
    disease usually appear 3-6 days after infection. the first stage of
    was characterized by fever, muscle pain, headache, chills, and after 3-4 days, most patients improved and their symptoms disappeared.
    However, in a few cases, the disease entered the "toxicity" phase, and about 50 per cent of patients who entered the toxic phase died within 10-14 days.
    Tychan, a Singapore-based biotech company, announced today that a study in the New England Journal of Medicine (NEJM) demonstrated the safety and effectiveness of monoclonal antibody TY014 in the treatment of yellow fever (YF). Professor Ram Sasisekharan, founder of
    Tychan, said: "It is imperative to quickly find a cure for yellow fever, as outbreaks of infectious diseases will become more frequent and will have significant social and economic impacts.
    COVID-19 pandemic is an example." The phase Ia study of
    evaluated the safety, tolerance and pharmacokinetics of monoclonal antibody TY014 in healthy volunteers, consisted of five random queues, double-blinddesigned the first dose cohort (0.5 mg / kg) and designed an open label scheme.
    the remaining four dosing groups are 2, 5, 10 and 20 mg / kg.
    22 volunteers received TY014 and five received placebos.
    this phase of the study reached the endpoint of safety and efficacy: 100% of the subjects inthesion were negative for viral blood disorder within 48 hours of infusion.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.